Purpose: According to American Society of Clinical Oncology/College of American Pathologists guidelines, breast cancer is human epidermal growth factor receptor 2 (HER2) positive if there is HER2 protein overexpression at a 3+ level on immunohistochemistry (IHC 3+) or gene amplification (more than six copies per nucleus) on fluorescence in situ hybridization (FISH+). However, there have been few reports on whether outcomes differ based on diagnosis by these two techniques. In this study, we compared outcomes based on the two methods in patients with HER2-positive breast cancer. Methods: This study was a retrospective analysis of HER2-positive breast cancer in 18,304 patients, including 14,652 IHC 3+ patients and 3,652 FISH+ patients from the Korean Breast Cancer Society Registry. We compared breast cancer-specific survival and overall survival based on IHC 3+ and FISH+ status with or without trastuzumab. Results: Breast cancer-specific survival was significantly different between the IHC 3+ and FISH+ groups, with 5-year cumulative survival rates of 95.0% for IHC 3+ and 98.5% for FISH+ patients who did not receive trastuzumab (p= 0.001) in Kaplan-Meier methods. However, there were no significant differences in breast cancer-specific survival and overall survival between IHC 3+ and FISH+ groups regardless of trastuzumab treatment in Cox proportional hazards models. Conclusion: The survival outcomes were not affected by the different two diagnostic methods of HER2-positive breast cancer. Further research to evaluate differences in prognosis and other characteristics according to the diagnostic methods of HER2 positivity is needed in the future.
INTRODUCTION
Human epidermal growth factor receptor 2 (HER2), a transmembrane receptor tyrosine kinase that is encoded on the long arm of chromosome 17 (17q12-21.32), is involved in tumor growth and progression. Overexpression of HER2 and gene amplification are displayed in 15% to 20% of breast cancer patients and are associated with aggressive cancer and a poor prognosis [1] [2] [3] [4] .
Trastuzumab, a representative targeted therapeutic agent for HER2-positive breast cancer, acts to arrest the cell cycle G1 phase and blocks cell proliferation with a humanized monoclonal antibody attached to the extracellular domain of the HER2 receptor. The drug, approved by the Food and Drug Administration (FDA) in 1998, has helped improve survival outcomes in both adjuvant and metastatic settings for HER2-positive breast cancer [5] [6] [7] [8] . Clinical trials, such as NSABP B-31 and NCCTG N9831, have shown that the addition of trastuzumab in an adjuvant setting increases disease-free survival [9] .
Since such HER2-targeted therapies are only indicated for HER2-positive breast cancer, identification of HER2 positivity is important [10] .
HER2 positivity is generally determined by immunohistochemistry (IHC), which measures the degree of overexpression of the HER2 protein. Although IHC is inexpensive and easy to perform, HER2 positivity may often be difficult to conclusively determine due to specimen heterogeneity and reader subjectivity in the interpretation of HER2 protein expression level [11] . The HER2 in situ hybridization (ISH) method, which measures HER2/neu gene amplification, is used in cases equivocal by IHC. ISH encompasses fluorescence ISH (FISH), chromogenic ISH, silver ISH (SISH), and dual color ISH [7] . FISH, in particular, has excellent sensitivity and specificity and is used as a golden standard in this setting [10] .
According to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, an IHC score of 3+ or gene amplification of more than six copies per nucleus by ISH qualifies as HER2 positive [6] . Although HER2 protein overexpression and HER2/neu gene amplification are closely related to each other, a debate remains on whether there is a difference in prognosis between the two for diagnosing HER2 cancer [12, 13] . The aim of this study was to compare prognosis between the two methods in HER2-positive breast cancer patients.
METHODS
In this study, we used materials approved by the Korean Breast Cancer Society registration system (KBCR). KBCR has been registering cases submitted by breast surgeons at 110 training hospitals nationwide since 1996 and has previously been described in detail [14] [15] [16] [17] . The cause and date of death in the documents were used in con- Immunohistochemistry IHC follows a 4-step scoring system from 0 to 3+, which depends on the immunostaining intensity in the cell membrane of the tissue specimen, as a way to measure the amount of HER2 protein in paraffin sections of breast cancer tissue. According to ASCO/CAP guidelines, specimens are classified as 0 to absent, 1+ to faint, 2+ to weak, and 3+ to intense from more than 10% cells [18] . A score of 3+ is asso- 
Statistical analysis
Prognosis was compared using the SAS System for Windows ver- 
RESULTS

Clinicopathological characteristics
The median follow-up period was 65 months (range, 0-234 months) in the 18,304 patients. zumab, FISH+ was more associated with nuclear grade (grade 2-3), and IHC 3+ was more associated with axillary dissection and negative hormonal receptor status (Table 4) .
Survival comparisons
In survival comparisons using the Kaplan-Meier method, 5-year cumulative survival rates of the whole HER2 subtype cohort were 95.7% and 90.8% for breast cancer-specific survival and overall survival, respectively. According to the presence or absence of trastuzumab treatment, 5-year cumulative survival rates were 99.1% and 95.2%
for breast cancer-specific survival and 94.3% and 90.3% for overall survival, respectively. The HER2 subtype cohort was significantly different according to the pathologic stage in both breast cancer-specific survival and overall survival (Figure 2 (Table 6 ).
DISCUSSION
Implicated in the growth of breast cancer, the HER2 receptor has become a target for breast cancer therapy. Since the discovery of the HER2/neu oncogene, FISH has helped overcome the diagnostic ambiguity of the existing IHC method for determining HER2 positivity [19, 20] . HER2 gene amplification in FISH is more than 90% identical to HER2 receptor protein overexpression, and HER2 positivity is related to prognosis. However, in some cases, there may be overexpression of the HER2 receptor without HER2 gene amplification, and vice versa, leading to inconsistent results [21] . Although FISH is used as a gold standard for measuring HER2/neu gene amplification, SISH has been shown to be as feasible as FISH to determine HER2 status in some recent studies [22] .
Correlations between these two diagnostic methods in HER2-positive breast cancer differ from study to study. Petroni et al. [12] reported that HER2-positive breast cancer showed unfavorable features in patients exhibiting gene amplification in FISH, even though the In contrast, Toi et al. [24] reported that in patients with metastatic HER2-positive breast cancer, overall survival was significantly higher in the group with a higher degree of HER2 expression, and the effects of trastuzumab could be seen. Lipton et al. [25] reported that most There are also studies where the results of these two methods do not vary. Zabaglo et al. [13] reported that in the Herceptin Adjuvant (HERA) trial of early-stage breast cancer patients, HER2 staining intensity and FISH amplification had a positive correlation, independent of the degree of HER2 staining intensity; however, disease-free survival was similar in both the presence and absence of trastuzumab.
Xu et al. [26] reported that the HER2 amplification level was not an effective prognostic factor, finding no significant difference in disease-free survival based on a meta-analysis of trastuzumab use in HER2 positive patients.
We observed a difference between the IHC 3+ and FISH+ groups in relation to other clinical factors. When analyzed according to the [29, 30] . It is thought that additional relevant studies are required under equivalent conditions. In addition, interpretation of IHC staining by pathologists has a subjective element, potentially introducing selection bias. Finally, there were few breast cancer-specific deaths in our cohort, making it difficult to compare detailed survival rates.
In this study, the breast cancer-specific survival and overall survival were not affected by the different two diagnostic methods of HER2-positive breast cancer in Cox proportional hazard models. A strength of this study is that we objectively evaluated no difference in survival outcome between the diagnostic methods using a large-scale dataset to overcome the limitations of previous controversial studies, such as small sample size. Further research to evaluate differences in prognosis and other characteristics according to the diagnostic methods of HER2 positivity is needed in the future.
